Literature DB >> 1502579

Plain radiographic predictors of survival in treated Ewing's sarcoma. IESS Committee.

W R Reinus1, E A Gehan, L A Gilula, M Nesbit.   

Abstract

We analyzed 16 radiographic features of primary Ewing's sarcoma in 342 patients from the IESS 7299 (Intergroup Ewing's Sarcoma Study) for prognostic significance. Of these, 3 features demonstrated a statistically significant relationship to survival: maximal tumor dimension, tumor location, and an appearance of honey-combing within the lesion. Those individuals with primary lesions centered in the pelvis, femur, or humerus had a worse survival rate than those with lesions centered elsewhere. Similarly, we observed an inverse relationship between the greatest dimension of the osseous portion of the lesion and survival. The radiographic finding of honeycombing also showed a statistical association with improved survival. However, this feature was observed infrequently, and its significance should be assessed further. Otherwise, no other feature that we analyzed showed any relationship to patient prognosis.

Entities:  

Mesh:

Year:  1992        PMID: 1502579     DOI: 10.1007/bf00241765

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  10 in total

1.  Combined modality therapy of Ewing's sarcoma.

Authors:  T C Pomeroy; R E Johnson
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

2.  Ewing's sarcoma. A clinicopathological and statistical analysis of patients surviving five years or longer.

Authors:  D J Pritchard; D C Dahlin; R T Dauphine; W F Taylor; J W Beabout
Journal:  J Bone Joint Surg Am       Date:  1975-01       Impact factor: 5.284

3.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

Authors:  M E Nesbit; E A Gehan; E O Burgert; T J Vietti; A Cangir; M Tefft; R Evans; P Thomas; F B Askin; J M Kissane
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

4.  Ewing's sarcoma.

Authors:  M E Nesbit
Journal:  CA Cancer J Clin       Date:  1976 May-Jun       Impact factor: 508.702

5.  Estimating rate of growth in bone lesions: observer performance and error.

Authors:  G S Lodwick; A J Wilson; C Farrell; P Virtama; F M Smeltzer; F Dittrich
Journal:  Radiology       Date:  1980-03       Impact factor: 11.105

6.  Prognostic factors in children with Ewing's sarcoma.

Authors:  E A Gehan; M E Nesbit; E O Burgert; J Viettit; M Tefft; C A Perez; J Kissane; C Hempel
Journal:  Natl Cancer Inst Monogr       Date:  1981-04

7.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study.

Authors:  M E Nesbit; C A Perez; M Tefft; E O Burgert; T J Vietti; J Kissane; D J Pritchard; E A Gehan
Journal:  Natl Cancer Inst Monogr       Date:  1981-04

8.  Radiotherapy and combination chemotherapy in advanced Ewing's Sarcoma-Intergroup study.

Authors:  M V Pilepich; T J Vietti; M E Nesbit; M Tefft; J Kissane; E O Burgert; D Pritchard
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860

9.  Intergroup Ewing's Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing's sarcoma.

Authors:  A Razek; C A Perez; M Tefft; M Nesbit; T Vietti; E O Burgert; J Kissane; D J Pritchard; E A Gehan
Journal:  Cancer       Date:  1980-08-01       Impact factor: 6.860

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  10 in total
  1 in total

1.  Imaging features and clinical course of undifferentiated round cell sarcomas with CIC-DUX4 and BCOR-CCNB3 translocations.

Authors:  Emily J Brady; Meera Hameed; William D Tap; Sinchun Hwang
Journal:  Skeletal Radiol       Date:  2020-08-25       Impact factor: 2.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.